Results 131 to 140 of about 223,857 (311)
Multiple Sclerosis Relapse Activity After Ozanimod Discontinuation in DAYBREAK Trial Participants
Annals of Clinical and Translational Neurology, EarlyView.Multiple Sclerosis Relapse Activity After Ozanimod Discontinuation in DAYBREAK Trial Participants. ABSTRACT Objective Return of disease activity is expected when patients discontinue disease‐modifying therapy (DMT) for multiple sclerosis (MS). Some MS DMTs are associated with higher‐than‐expected disease activity (rebound) after discontinuation.
Ralf Gold +12 more
wiley +1 more source
Analyzing busway station potential capacity under mixed stopping and non-stopping operation
, 2015 Busway stations are the interface between passengers and services. The station is crucial to line operation as it is typically the only location where buses can pass each other.
Bunker, Jonathan M. +2 more
core
[18F]Fluorodeprenyl‐D2 PET as a Tool to Monitor Disease Activity in GAD65‐Ab Autoimmune Encephalitis
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective To evaluate [18F]fluorodeprenyl‐D2 ([18F]F‐DED) positron‐emission tomography (PET) imaging as a biomarker of disease activity in autoimmune encephalitis (AIE) associated with glutamic acid decarboxylase 65 (GAD65) antibodies. Methods [18F]F‐DED PET was performed in 25 GAD65‐AIE patients and 8 controls using dynamic (0–60 min) and ...
Julia S. Dorneich +19 more
wiley +1 more source
Electronic MaterialsMonolayer and few-layer MoS2 are promising two-dimensional electronic materials, but proton irradiation can trigger ultrafast electronic excitation and charge transfer before defect formation.
Ligang Wang +3 more
doaj +1 more source
Analysing busway station capacity under mixed stopping and non-stopping operation
, 2015 Busway stations are the interface between passengers and services. The station is crucial to line operation as it is typically the only location where buses can pass each other.
Bunker, Jonathan M. +2 more
core
Optimal multiple stopping time problem
, 2011 International audienceWe study the optimal multiple stopping time problem defined for each stopping time S by v(S) = ess sup(tau 1), ... , (tau d) (>=) (S) E[psi(tau(1), ... , tau(d))vertical bar F-S].The key point is the construction of a new reward phi
Rouy-Mironescu, E. +5 more
core +1 more source
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective To (1) validate GAD65‐ELISA detection and quantification for type 1 diabetes mellitus and autoimmune neurological diagnoses, (2) correlate ELISA results (reference range < 5 IU/mL) with established radioimmunoprecipitation assay (RIA; ≤ 0.02 nmol/L), and (3) define ELISA clinical utility and pitfalls.
Andrew McKeon +11 more
wiley +1 more source
Stopping at the Last Renewal Up to a Terminal Time
, 2013 [[abstract]]Given a renewal process and a fixed terminal time , we want to find a strategy that maximizes the probability of stopping, without recall, at the last renewal up to .
Hsiau, Shoou-Ren
core
Time-consistent stopping under decreasing impatience
, 2017 International audienceUnder non-exponential discounting, we develop a dynamic theory for stopping problems in continuous time. Our framework covers discount functions that induce decreasing impatience.
Nguyen-Huu, Adrien +3 more
core +1 more source
RNA Sequencing Resolves Cryptic Pathogenic Variants in Mitochondrial Disease
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective Mitochondrial diseases are the most common inherited metabolic disorders, characterized by pronounced clinical and genetic heterogeneity that complicates molecular diagnosis. Although DNA‐based sequencing approaches have become standard in genetic testing, up to half of patients remain without a definitive diagnosis.
Zhimei Liu +21 more
wiley +1 more source